US 7,605,236 B2 · Antibodies that immunospecifically bind to B lymphocyte stimulator protein

Abstract

The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.

Claims25

Dependent claims

An isolated or purified antibody that immunospecifically binds to B Lymphocyte Stimulator protein comprising:

(a) an amino acid sequence that is at least 85% identical to residues 1-126 of SEQ ID NO:1321;
and
(b) an amino acid sequence that is at least 85% identical to residues 143-251 of SEQ ID NO:1049;
wherein the B Lymphocyte Stimulator protein is selected from the group consisting of:
(1) a protein whose amino acid sequence consists of amino acid residues 1-285 of SEQ ID NO:3228;
(2) a protein whose amino acid sequence consists of amino acid residues 134-285 of SEQ ID NO:3228;
and
(3) a trimer of the protein of (2).

5 more elements

Dependencies are inferred from the claim text.

Facts

Application

11/266,444Filed 4 Nov 2005 · division

Priority

16 Jun 2000

Published

US 2006/0062789 A123 Mar 2006

Granted

20 Oct 2009

Term ends

Not estimatedThe source records don’t support an estimate.

Classification22 codes

C07K 14/70575
Receptors; Cell surface antigens; Cell surface determinants: ngf/tnf-superfamily, e.g. cd70, cd95l, cd153, cd154
A61K 47/6849
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a receptor, a cell…
A61K 49/0004
Preparations for testing in vivo: screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance,…
A61P 19/02
Drugs for skeletal disorders: for joint disorders, e.g. arthritis, arthrosis

Family

Application60/212,210Us provisional application · filed 16 Jun 2000

Application60/240,816Us provisional application · filed 17 Oct 2000

Application60/276,248Us provisional application · filed 16 Mar 2001

Application60/277,379Us provisional application · filed 21 Mar 2001

Application60/293,499Us provisional application · filed 25 May 2001

Application09/880,748Parent of this division · filed 15 Jun 2001

US 2006/0062789 A1Pre-grant publication · published 23 Mar 2006

US 7,138,501 B2Parent of this division

US 2003/0059937 A1Published application

US 7,605,236 B2This patent

From the US filing history. Foreign family members aren’t listed.

Antibodies that immunospecifically bind to B lymphocyte stimulator protein

Life of this patent

Antibodies that immunospecifically bind to B lymphocyte stimulator protein

Life of this patent

Abstract

Claims25